Medfinder
Back to blog

Updated: January 26, 2026

How Does Anastrozole Work? Mechanism of Action Explained in Plain English

Author

Peter Daggett

Peter Daggett

Body silhouette with anastrozole mechanism of action glowing pathways

How does anastrozole fight breast cancer? This plain-English guide explains the science behind anastrozole's mechanism of action — how it blocks estrogen to stop cancer growth.

Anastrozole is one of the most effective treatments for hormone receptor-positive breast cancer — but how exactly does it work? Understanding the science behind your medication can help you feel more confident about your treatment. This guide explains anastrozole's mechanism of action in plain English, without requiring a biology degree.

The Role of Estrogen in Breast Cancer

Not all breast cancers are the same. About 75–80% of breast cancers are "hormone receptor-positive" — meaning the cancer cells have receptors (think of them as docking ports) for the hormone estrogen. When estrogen binds to these receptors, it sends signals that tell the cancer cells to grow and divide. This is why these tumors are called "estrogen-dependent."

The logical treatment strategy: reduce the amount of estrogen available to feed these cancer cells. That's exactly what anastrozole does.

What Is Aromatase?

In premenopausal women, the ovaries are the main source of estrogen. After menopause, the ovaries stop producing estrogen — but the body doesn't stop making it entirely. Instead, a small but clinically significant amount of estrogen continues to be produced in peripheral tissues, including fat tissue, muscle, skin, liver, and even within breast tumor tissue itself.

This peripheral estrogen production depends on an enzyme called aromatase. Aromatase acts as a biological converter — it takes androgens (hormones produced by the adrenal glands) and converts them into estrogens. Specifically:

Androstenedione → Estrone (E1)

Testosterone → Estradiol (E2)

Estradiol is the most potent form of estrogen and the most important driver of hormone receptor-positive breast cancer growth. After menopause, aromatase-mediated conversion in peripheral tissues becomes the primary — and sometimes the only — significant source of estradiol in a woman's body.

How Anastrozole Blocks Aromatase

Anastrozole is a selective, non-steroidal aromatase inhibitor. It works by binding to the aromatase enzyme and blocking its active site — preventing it from converting androgens to estrogens. This is called competitive inhibition: anastrozole competes with androgens for the enzyme's binding site and, when present at the therapeutic dose, wins that competition.

The word "selective" in its description is important: anastrozole specifically targets aromatase without significantly affecting other enzymes or hormone production systems. In particular, it has no detectable effect on the production of adrenal corticosteroids or aldosterone — meaning it doesn't disrupt your adrenal gland function at the standard 1 mg daily dose.

How Much Does Anastrozole Lower Estrogen?

Anastrozole at 1 mg daily reduces serum estradiol levels by approximately 80–96% in postmenopausal women. This is a dramatic reduction that significantly deprives estrogen-sensitive tumor cells of the hormone they need to grow. The drug reaches steady-state plasma concentrations in about 7 days of daily dosing.

Reversible vs. Irreversible Inhibition: How Anastrozole Differs from Exemestane

Anastrozole binds to aromatase reversibly — meaning when anastrozole is cleared from the body, aromatase can return to normal function. This is different from exemestane (Aromasin), a steroidal aromatase inactivator that permanently binds to and destroys aromatase enzyme molecules (irreversible inhibition). Both approaches are clinically effective, but they have slightly different properties and side effect profiles.

Why Anastrozole Doesn't Work in Premenopausal Women

In premenopausal women, the ovaries are the primary estrogen source — and aromatase inhibitors don't affect ovarian estrogen production directly. When anastrozole blocks peripheral aromatase, the brain senses lower estrogen levels and signals the ovaries to produce more estrogen to compensate. The result is that estrogen levels don't fall — and anastrozole doesn't work. That's why anastrozole is only approved for postmenopausal women, or premenopausal women who have their ovarian function suppressed by a separate medication (like a GnRH agonist).

From Molecule to Medicine: How Quickly Does It Start Working?

After taking your first dose of anastrozole, the drug is rapidly absorbed — reaching peak plasma concentrations within 2 hours on an empty stomach (5 hours if taken with food, though the total absorption is the same). Anastrozole has a half-life of approximately 40–50 hours, meaning it stays in your system for several days. It typically takes about 7 days of daily dosing to reach steady-state levels and achieve its full estrogen-suppressing effect. The clinical response in terms of breast cancer control develops over weeks to months.

Want to Learn More?

See our complete guide on what anastrozole is, its uses, and dosage and learn about anastrozole side effects and when to call your doctor.

Frequently Asked Questions

Anastrozole blocks the aromatase enzyme, which converts androgens (male hormones) into estrogen in peripheral tissues. By dramatically reducing estrogen levels (by approximately 80–96%), anastrozole deprives estrogen-sensitive (HR-positive) breast cancer cells of the hormone they need to grow and divide. It is effective in postmenopausal women because they rely on peripheral aromatase — not the ovaries — as their primary estrogen source.

No. Anastrozole is a hormone therapy — specifically an aromatase inhibitor. It does not kill cancer cells directly like traditional chemotherapy. Instead, it deprives hormone-sensitive cancer cells of estrogen, slowing or stopping their growth. Anastrozole does not cause the hair loss, nausea, or immune suppression associated with cytotoxic chemotherapy.

Anastrozole reaches steady-state estrogen-suppressing levels within about 7 days of daily dosing. The clinical benefit in terms of cancer control — tumor shrinkage or reduction in recurrence risk — develops over weeks to months. Do not judge the effectiveness of anastrozole based on short-term changes; clinical benefit is typically measured over years.

In premenopausal women, the ovaries are the dominant source of estrogen. Aromatase inhibitors block peripheral estrogen production, not ovarian production. When an aromatase inhibitor is given to a premenopausal woman, her body compensates by having her ovaries produce more estrogen. The net result is no significant reduction in estrogen levels — and no clinical benefit for breast cancer treatment.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards

Patients searching for Anastrozole also looked for:

37,190 have already found their meds with Medfinder.

Start your search today.

37K+
5-star ratingTrusted by 37,190 Happy Patients
      What med are you looking for?
⊙  Find Your Meds
99% success rate
Fast turnaround time
Never call another pharmacy

Need this medication?